Abstract
In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Current Vascular Pharmacology
Title:Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Volume: 12 Issue: 4
Author(s): Manfredi Rizzo, Milan Obradovic, Milica Labudovic-Borovic, Dragana Nikolic, Giuseppe Montalto, Ali A. Rizvi, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Abstract: In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, Obradovic Milan, Labudovic-Borovic Milica, Nikolic Dragana, Montalto Giuseppe, Rizvi A. Ali, Mikhailidis P. Dimitri and Isenovic R. Esma, Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/1570161111999131205160756
DOI https://dx.doi.org/10.2174/1570161111999131205160756 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Variation of Antioxidant Capacity in Different Layers of Onion (Allium cepa L.) At Two Different Stages of Maturation
Current Nutrition & Food Science Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Biological Roles of the Eclectic Chromogranin-A-derived Peptide Catestatin
Current Medicinal Chemistry Biofilm Inhibition of Spoilage Bacteria by Argentinean Fruit Juices with Antihypertensive Activity
Current Pharmaceutical Biotechnology Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Inflammation in Hypertension: Current Therapeutic Approaches
Current Pharmaceutical Design Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy ACE Inhibitor-Angiotensin Receptor Blocker Combinations: A Clinicians Perspective
Mini-Reviews in Medicinal Chemistry Global Cardiovascular Risk Management in Primary Prevention
Current Vascular Pharmacology Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Molecular Counting of Captopril by a Microfluidic Chip-Thermal Lens Microscopy System
Current Analytical Chemistry Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Releasing the Genie in the Bottle: Molecular Signaling with Hydrogen Sulfide
Current Neurovascular Research Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model
Current Pharmaceutical Biotechnology Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Antihypertensive Drugs that Act on Renin-Angiotensin System with Emphasis in AT1 Antagonists
Mini-Reviews in Medicinal Chemistry Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology